Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 387NIH 50INDUSTRY 18NETWORK 12OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Neoplasms, Plasma Cell 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1

Interventions

fludarabine 5Cyclophosphamide 5Azacitidine 4Cytarabine 3venetoclax 2pegylated granulocyte colony-stimulating factor 2bisantrene 2Metformin 2Etoposide 2Dasatinib 2Clofarabine 2Busulfan 2vosaroxin 1treosulfan 1peginterferon alfa-2a 1nilotinib 1liposomal amphotericin B 1fludarabine phosphate 1defactinib 1decitabine and cedazuridine drug combination 1cedazuridine 1cc-486 1aldesleukin 1Zinc Sulfate 1Zinc 1Vitamin D 1Urination 1Tranexamic Acid 1Thiotepa 1Thalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × fludarabine phosphate × Other hematologic neoplasm × Clear all
NCT05528887 2022-09-06

Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

The Affiliated People's Hospital of Ningbo University

Phase 1 Recruiting
10 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Hematologic Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡